DuPont (DD) Q1 2026 earnings review
The 'New DuPont' Shines: Margins Surge as Transformation Completes
DuPont's first quarter as a fully streamlined multi-industrial company delivered a clean beat-and-raise. With the Electronics spin-off and Aramids divestiture complete, the core portfolio proved its earnings power. While top-line growth was a modest 4% (2% organic), profitability accelerated dramatically: Operating EBITDA jumped 15% and Adjusted EPS surged 53% to $0.55. Margin expansion of 230 basis points was driven by favorable mix and operational productivity. Management raised full-year guidance and signaled confidence by launching an immediate $275 million accelerated share repurchase.
🐂 Bull Case
Operating EBITDA margins expanded 230 basis points to 24.6%. The company is successfully leveraging mix and productivity to generate double-digit earnings growth from low-single-digit sales growth.
With portfolio distractions removed and a $1.2 billion cash injection from the April 1 Aramids sale, the company is aggressively buying back stock while boasting >60% free cash flow conversion.
🐻 Bear Case
The Diversified Industrials segment showed flat organic growth, held back by persistent weakness in construction end-markets and declines in printing and packaging.
Middle East logistics disruptions actively suppressed Water Technologies revenue, showing vulnerability to external supply chain shocks.
⚖️ Verdict: 🟢
Bullish. DuPont is successfully executing the classic 'shrink to grow' playbook. The core portfolio is delivering substantial margin expansion, and the guidance raise indicates visibility into accelerating H2 demand.
Key Themes
Healthcare Technologies Outperformance
The Healthcare & Water Technologies segment led the company with a 30.3% EBITDA margin. Growth was anchored by the Healthcare unit, which grew high-single digits organically. Consistent demand for medical packaging (Tyvek) and biopharma solutions continues to provide a highly profitable, cycle-resistant revenue base.
Water Technologies Dragged by Middle East Logistics
Contradicting the broader segment's strength, Water Technologies organic sales declined low-to-mid single digits. Management noted this was entirely due to logistics disruptions in the Middle East, which offset solid underlying demand in industrial water and microelectronics. This presents an acute, external risk to near-term execution.
Pricing Power Offsets Geopolitical Headwinds
Despite facing higher input costs related to the Middle East conflict, management was able to implement ~1% in pricing actions. Combined with operational productivity, this allowed the company to fully offset the inflationary pressure and expand enterprise margins by 230 basis points.
Construction Market Weakness Stalls Diversified Industrials
The Diversified Industrials segment severely lagged the company average, posting flat organic growth. This was directly tied to the Building Technologies unit, which declined low-single digits due to ongoing cyclical weakness in global construction markets. Declines in the printing and packaging business further pressured the segment.
Aramids Divestiture Capitalizes the Balance Sheet
The April 1st closing of the Aramids business sale injected approximately $1.2 billion in pre-tax cash. Management wasted no time deploying capital, announcing a $275 million Accelerated Share Repurchase (ASR) to be launched imminently, utilizing part of the previously authorized $2 billion buyback program.
Other KPIs
Accelerating dramatically from just $8 million in 25Q1. Operating cash flow from continuing operations jumped 201% to $232 million, reflecting higher segment earnings, lower interest expenses, and a $48 million reduction in working capital. Free cash flow conversion hit a healthy 65%.
Decreasing. Down over 50% from $83 million in the prior-year period. Following the Qnity separation and associated debt paydowns in late 2025, DuPont's interest burden has been structurally lowered, providing a persistent tailwind to Adjusted EPS.
Guidance
Accelerating. Implies sequential growth of 7% over 26Q1 and expected organic YoY growth of ~3% (up from 2% organic growth in 26Q1). This indicates management sees order momentum building into the summer.
Accelerating sequentially from the $0.55 delivered in 26Q1, driven by expected higher volumes and the initial accretive impact of the $275 million Accelerated Share Repurchase.
Accelerating. Raised from the prior $7.075-$7.135B range. The new outlook now explicitly models ~4% organic growth for the full year, including ~1% of pricing. Because Q1 delivered 2% and Q2 is guided to 3%, hitting the full-year 4% target requires a significant acceleration in the second half of 2026.
Accelerating. Raised from the previous forecast of $2.25-$2.30. The $0.10 midpoint bump reflects a combination of the Q1 operational beat, interest income benefits from the Aramids transaction note, and lower share count from the ASR.
Key Questions
Middle East Logistics Resolution
With Water Technologies sales dropping due to logistics in the Middle East, are these orders permanently lost to competitors, or merely deferred to future quarters? What is the expected timeline for normalization?
H2 Organic Growth Acceleration
Full-year guidance implies 4% organic growth, while H1 is pacing closer to 2.5%. What specific end-market recoveries (e.g., Construction) are you relying on to drive the required acceleration in the second half?
Capital Deployment from Aramids
You received $1.2 billion in pre-tax cash from the Aramids sale on April 1 and announced a $275 million ASR. How should investors think about the cadence for deploying the remaining cash between further buybacks and M&A in the Healthcare space?